Flavopiridol was also shown to synergistically enhance the anti-myeloma effect of Bcl-2 antagonists, bortezomib and TRAIL, while seliciclib potentiates the anti-myeloma activity of doxorubicin and bortezomib [88, 90–92]. The gene discussed is TNFSF10; the disease is plasma cell myeloma.